Literature DB >> 319421

[Treatment of parkinsonian syndromes by bromocriptin].

J C Gautier, J P Durand.   

Abstract

Nine patients suffering from Parkinson's disease and 2 cases of Parkinsonian syndrome were treated with bromocriptine, for 41 to 117 days, with a daily dose of 20 to 40 mg. The results were very good in 4 cases, satisfactory in 6 and nil in one case. Improvement concerned akinesias, rigidity and tremor, and was more marked in patients with more advanced signs. In 2 patients, amantadine was stopped. The dose of L-dopa was decreased by 2/3 without any change in clinical condition and L-dopa could be withdrawn in 5 cases out of 8. Bromocriptine appears to be an interesting development in the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 319421

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  4 in total

1.  The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome).

Authors:  A J Lees; R Bannister
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-04       Impact factor: 10.154

2.  Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.

Authors:  T A Caraceni; I Celano; E Parati; F Girotti
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-12       Impact factor: 10.154

3.  Long-term treatment of Parkinson's disease with bromocriptine.

Authors:  A Rascol; B Guiraud; J L Montastruc; J David; M Clanet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-02       Impact factor: 10.154

4.  Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.

Authors:  K Jellinger
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.